126 related articles for article (PubMed ID: 37915108)
1. Predictors of the development of febrile neutropenia in chemotherapy for advanced germ cell tumors.
Kobayashi K; Kishida T
Int J Urol; 2024 Feb; 31(2):134-138. PubMed ID: 37915108
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
[TBL] [Abstract][Full Text] [Related]
3. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
4. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
Leon Rapoport B; Garcia-Morillo M; Font C; Samoon Z; Jabbar AA; Kourie HR; Kayumba A; Esposito F; Popescu RA; García-Gómez J; Heyman L; Smit T; Krendyukov A; Mathieson N; Cooksley T; Anderson R; Klastersky J
Support Care Cancer; 2023 Oct; 31(12):628. PubMed ID: 37828258
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
6. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
[TBL] [Abstract][Full Text] [Related]
7. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
[TBL] [Abstract][Full Text] [Related]
8. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
9. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
11. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas.
Chan A; Lee CP; Chiang J; Ng R
Support Care Cancer; 2013 Aug; 21(8):2137-43. PubMed ID: 23471537
[TBL] [Abstract][Full Text] [Related]
13. Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia.
Căinap C; Cetean-Gheorghe S; Pop LA; Leucuta DC; Piciu D; Mester A; Vlad C; Ovidiu C; Gherman A; Crişan C; Bereanu A; Bălăcescu O; Constantin AM; Dicu I; Bălăcescu L; Stan A; Achimaş-Cadariu P; Căinap S
Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34208815
[TBL] [Abstract][Full Text] [Related]
14. Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
Suzuki K; Sasada S; Nishi H; Kimura Y; Shintani T; Emi A; Masumoto N; Kadoya T; Kawaguchi H; Okada M
Breast Cancer; 2023 Jan; 30(1):151-155. PubMed ID: 36271187
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
16. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China.
Zheng W; Chen Z; Zhu S; Cheng L; Hu Y; Yang Y; Tan M; Ning H; Guan L
Support Care Cancer; 2023 Dec; 32(1):43. PubMed ID: 38200251
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The
Aagaard T; Reekie J; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
Int J Cancer; 2020 Jan; 146(2):321-328. PubMed ID: 30839100
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
20. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
